Literature DB >> 2297568

Tumor cells are the site of erythropoietin synthesis in human renal cancers associated with polycythemia.

J L Da Silva1, C Lacombe, P Bruneval, N Casadevall, M Leporrier, J P Camilleri, J Bariety, P Tambourin, B Varet.   

Abstract

One to five percent of human renal cell carcinomas are associated with polycythemia. It is generally assumed that polycythemia results from the secretion of erythropoietin (Epo) by the malignant cells. However, there is no direct proof supporting this hypothesis. Three patients with typical renal adenocarcinoma and polycythemia were studied. All three exhibited high Epo serum levels as measured by radioimmunoassay (RIA). A strong Epo signal was observed on Northern blot analysis of total RNA extracted from the renal tumors. The Epo message seemed to be of normal size and no Epo gene rearrangement was observed with the restriction enzymes tested. Using the in situ hybridization technique, a significant labeling was constantly observed on the tumor cells. Immunohistochemical studies showed that these tumor cells, known to be of tubular origin, were labeled by an anti-cytokeratin antibody and therefore were of epithelial nature. Thus, this study demonstrated that malignant cells of tubular origin were able to produce Epo constitutively, whereas in the mouse hypoxic kidney, peritubular cells (probably capillary endothelial cells) were the major site of Epo synthesis.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2297568

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  25 in total

1.  Transient ischaemic attack secondary to paraneoplastic erythrocytosis.

Authors:  Aldo René Hurtarte Sandoval; Bryan Josué Flores Robles; Robert Francis Andrus; David Alejandro Yaxcal Chon
Journal:  BMJ Case Rep       Date:  2014-10-21

2.  Vascular damage without hypertension in transgenic rats expressing prorenin exclusively in the liver.

Authors:  M Véniant; J Ménard; P Bruneval; S Morley; M F Gonzales; J Mullins
Journal:  J Clin Invest       Date:  1996-11-01       Impact factor: 14.808

3.  Vertebral artery thrombosis: a rare presentation of primary polycythaemia.

Authors:  H L Gul; S Y M Lau; D Chan-Lam; J-P Ng
Journal:  BMJ Case Rep       Date:  2014-05-26

4.  Inactivation of the arylhydrocarbon receptor nuclear translocator (Arnt) suppresses von Hippel-Lindau disease-associated vascular tumors in mice.

Authors:  Erinn B Rankin; Debra F Higgins; Jacqueline A Walisser; Randall S Johnson; Christopher A Bradfield; Volker H Haase
Journal:  Mol Cell Biol       Date:  2005-04       Impact factor: 4.272

Review 5.  [Paraneoplastic syndrome in renal cell carcinoma].

Authors:  J Bedke; S Buse; M Kurosch; A Haferkamp; D Jäger; M Hohenfellner
Journal:  Urologe A       Date:  2007-01       Impact factor: 0.639

Review 6.  The VHL tumor suppressor in development and disease: functional studies in mice by conditional gene targeting.

Authors:  Volker H Haase
Journal:  Semin Cell Dev Biol       Date:  2005-04-26       Impact factor: 7.727

7.  HIF-1 and HIF-2: working alone or together in hypoxia?

Authors:  Peter J Ratcliffe
Journal:  J Clin Invest       Date:  2007-04       Impact factor: 14.808

8.  Prevalence of paraneoplastic erythropoietin production by renal cell carcinomas.

Authors:  A J Gross; M Wolff; J Fandrey; W D Miersch; K P Dieckmann; W Jelkmann
Journal:  Clin Investig       Date:  1994-05

9.  Impact of increased erythropoietin receptor expression and elevated serum erythropoietin levels on clinicopathological features and prognosis in renal cell carcinoma.

Authors:  Keiichi Ito; Hidehiko Yoshii; Takako Asano; Akio Horiguchi; Makoto Sumitomo; Masamichi Hayakawa; Tomohiko Asano
Journal:  Exp Ther Med       Date:  2012-03-13       Impact factor: 2.447

Review 10.  The VHL tumor suppressor and HIF: insights from genetic studies in mice.

Authors:  P P Kapitsinou; V H Haase
Journal:  Cell Death Differ       Date:  2008-01-25       Impact factor: 15.828

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.